Novel dual endothelin-receptor antagonist—-—Aprocitentan

VernacularTitle:新型双重内皮素受体拮抗药——Aprocitentan
Author: Yuan-Kui WEI ^{1
,

2} ; Bao-Qiang ZHU ; Ming-Ming ZHANG ; Shi-Yu YANG ; En-Wu LONG
Author Information

1. 西南医科大学药学院,四川泸州 646000
2. 四川省医学科学院·四川省人民医院实验动物研究所,四川成都 610212
Keywords: Aprocitentan; endothelin receptor antagonist; resistant hypertension
From: The Chinese Journal of Clinical Pharmacology 2024;40(20):3047-3050
CountryChina
Language:Chinese
Abstract: Aprocitentan is a dual endothelin receptor antagonist.Based on the effective evidence of Ⅲ phases of clinical trials,the drug was approved for marketing by the U.S.Food and Drug Administration on March 19,2024 for the treatment of refractory hypertension.At present,multiple clinical studies have confirmed that Aprocitentan has excellent antihypertensive effects and good tolerability.This article reviews the pharmacological effects,preclinical.